Revision 3

#3196 Store at -20C

Basic FGF (19A9) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H	Recombinant protein	19	Rabbit IgG	#P09038	2247

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

Basic FGF (19A9) Rabbit mAb detects recombinant human basic FGF at various concentrations. It may cross-react with human acidic FGF proteins at high concentration levels.

Source / Purification

Monoclonal antibody is produced by immunizing animals with recombinant human basic FGF proteins.

Background

Fibroblast growth factors are a family of broad-spectrum growth factors influencing a plethora of cellular activities. The interaction of at least 23 ligands, four receptors, and multiple coreceptors provides a dramatic complexity to a signaling system capable of effecting a multitude of responses (1,2). Basic fibroblast growth factor (bFGF or FGF2), initially identified as a mitogen with prominent angiogenic properties, is now recognized as a multifunctional growth factor (3). It is clear that bFGF produces its biological effects in target cells by signaling through cell-surface FGF receptors. bFGF binds to all four FGF receptors. Ligand binding induces receptor dimerization and autophosphorylation, allowing binding and activation of cytoplasmic downstream target proteins, including FRS-2, PLC, and Crk (4,5). The FGF signaling pathway appears to play a significant role not only in normal cell growth regulation but also in tumor development and progression (6).Acidic FGF (aFGF or FGF1) is another extensively investigated protein of the FGF family. aFGF shares 55% DNA sequence homology with bFGF. These two growth factors are ubiquitously expressed and exhibit a wide spectrum of similar biological activities with quantitative differences likely due to variations in receptor affinity or binding (7).

Background References

1. Powers, C.J. et al. (2000) *Endocrine-Related Cancer* 7, 165-197.
2. Bansal, R. (2002) *Dev. Neurosci.* 24, 35-46.
3. Morrison, R.S. et al. (1994) *J. Neurooncol.* 18, 207-216.
4. Kouhara, H. et al. (1997) *Cell* 89, 693-702.
5. Mohammadi, M. et al. (1991) *Mol. Cell. Biol.* 11, 5068-5078.
6. Bikfalvi, A. (1995) *Eur. J. Cancer* 31A, 1101-1104.
7. Ledoux, D. et al. (1992) *Prog. Growth Factor Res.* 4, 107-120.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.